A leading cancer research organisation has hit out at a recent study which attributes cancer to bad luck. The International Agency for Research on Cancer (IARC) said it strongly disagrees with the conclusion of the report on the causes of human ... Irish Examiner, 1 week ago
Obesity Responsible for almost Half-Million Cancers Annually - Med India, 2 months ago
Half a million cancer cases a year due to obesity: WHO - First Post.com, 2 months ago
Formaldehyde is considered a known human carcinogen by the International Agency for Research on Cancer. (Photo: ) E-cigarettes may not be as safe an alternative to cigarette smoking as hoped, according to a new study published in The New England ...Yahoo! News, 1 week ago E-cigarettes contain hidden formaldehyde, a known carcinogen Examiner.com, 3 days ago
h Columbia Cancer Agency, Canada addressed a nursing oncology symposium here today to promote excellence in research and leadership in the field for providing quality cancer care. Besides Savitri Singh Carlson, others included Dr Sarah Easow, Diplomat of the ...Business Standard, 2 weeks ago
by AFP January 26, 2015 Share this: Miami, Florida, United State — When heated to the max and inhaled deeply, e-cigarettes produce the toxic chemical formaldehyde, which could make the devices up to 15 times more cancerous than regular ...Manila Bulletin, 3 days ago Formaldehyde in e-cigarettes could boost cancer risk Japan Today, 4 days ago Cancer Risk Boosted by Formaldehyde in E-Cigarettes MedIndia, 1 week ago E-cigarettes: cancer risk 15 times greater than smoking cigarettes BizNews.com, 1 week ago
More from: Japan Times, Asiaone...and 10 other sources
Sleep well at night knowing that Montreal researchers have made a breakthrough in the science of snoozing.
Study shows how to reset your biological clock Written by: Anne Caroline Desplanques, QMI Agency Jan. 18, 2015 (Fotolia) MONTREAL -- Sleep disruptors such as jet lag and atypical working hours can be more than annoyances. Cancer, hypertension, ...C-Health, 1 week ago
OSE Pharma Appoints To Conduct Its Tedopi® Phase 3 International Clinical Trial In Advanced Lung Cancer Patients
PARIS, FRANCE, January 29th2015: OSE Pharma, a biotechnology company developing T-cell specific immunotherapy, and Simbec-Orion, a leading global clinical research organisation (CRO) with specialisation in oncology and rare diseases, announced today ...BioSpace, 5 hours ago OSE Pharma Collaboration for Cancer Trial TrustNet, 11 hours ago
Novartis announces study in NEJM showing Jakavi® was superior to standard therapy in rare blood cancer polycythemia vera
World News: 22:00 GMT Wednesday 28th January 2015 . [ Novartis International AG via Thomson Reuters ONE via SPi World News ] This story Novartis International AG / Novartis announces study in NEJM showing Jakavi® was superior to standard ...SPi World News, 1 day ago NOVARTIS : announces study in NEJM showing Jakavi® was superior to standard therapy in rare blood cancer polycythemia vera 4 Traders, 1 day ago NOVARTIS : drug Jakavi® recommended by CHMP for EU approval to treat adults with rare blood cancer polycythemia vera 4 Traders, 6 days ago Novartis drug Jakavi® recommended by CHMP for EU approval to treat adults with rare blood cancer polycythemia vera AndhraNews.net, 5 days ago
"There is widespread recognition that the threat of nuclear terrorism is one of the pressing challenges facing the international community. Responsible national action and effective international cooperation are therefore required for strengthening nuclear ...Jagran Post, 2 months ago India calls for intl action to strengthen nuclear security Deccan Herald, 2 months ago
Celgene Receives Positive CHMP Opinion for ABRAXANER for First-Line Treatment of Patients with Non-Small Cell Lung Cancer
-Celgene International Sarl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for ...Taiwan News Online, 6 days ago Celgene Reaffirms Earnings Whispers, 10 hours ago Celgene Sees FY EPS $3.68-EPS $3.92 >CELG iMarketReports, 10 hours ago PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2014 RESULTS; PROVIDES 2015 FINANCIAL GUIDANCE Pharmacy Choice, 2 days ago
Enumeral Biomedical : and Memorial Sloan Kettering Cancer Center to Research Cancer Immunology With Advanced Prototype System for Human Tissue Immuno-Oncology...
Enumeral and Memorial Sloan Kettering Cancer Center to Research Cancer Immunology With Advanced Prototype System for Human Tissue Immuno-Oncology Profiling By a News Reporter-Staff News Editor at Cancer Vaccine Week -- Enumeral Biomedical ...4 Traders, 6 days ago Enumeral and Memorial Sloan Kettering Cancer Center to Research Cancer Immunology With Advanced Prototype System for Human Tissue Immuno-Oncology... Pharmacy Choice, 3 days ago
on your WebpageAdd Widget >Get your members hooked!